Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Decide whether points or cash back is better for your travel needs. Explore the benefits of each to optimize your rewards strategy.
27,012 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Garmin delivered a dominant Q4 with a big EPS beat and revenue surge, triggering a sharp market rally as investors we...
A corporate insider sold a meaningful chunk of stock after a record revenue year. This article breaks down what such ...
A 54-year-old engineer designs a $1.6 million income plan to yield about $9,500 per month by age 67, blending REITs, ...
Looking for better income from corporate credit? This guide breaks down long corporate bond etfs like IGLB and VCLT, ...
Markets love headlines, but investors need a plan. This guide explains how presidential talk fits into long-term inve...
A high-profile insider sale at PTC Therapeutics coincides with a milestone for product revenue. This article breaks d...
Microsoft is riding a fast-growing AI wave, but its stock hasn’t followed the surge. Here’s how analysts and models v...
Ford's fourth quarter shocked many investors: a massive net loss despite solid revenue. This article peels back the d...
A hypothetical $10,000 Exxon investment at the outbreak of the Iran conflict has produced a mixed bag of results. Her...
Adobe sits as a candidate undervalued stock that could rebound in 2026, trading in the low-$280s with a 16x trailing ...
As AI spending shifts from hype to heavy borrowing, Goldman Sachs warns AI's debt tsunami may tighten credit markets....